- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BIOXYTRAN, INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.04. | BIOXYTRAN, INC - 10-K, Annual Report | - | SEC Filings | ||
| 01.04. | BIOXYTRAN, INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 13.03. | BIOXYTRAN, INC - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Bioxytran Reports Positive Dose Optimization Results, Advances ProLectin-M Toward Phase 3 Trial | - | RTTNews | ||
| 04.03. | BIOXYTRAN, INC.: Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | 580 | GlobeNewswire (Europe) | Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran... ► Artikel lesen | |
| 02.03. | Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 | 365 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized... ► Artikel lesen | |
| BIOXYTRAN Aktie jetzt für 0€ handeln | |||||
| 02.03. | BIOXYTRAN, INC - 8-K, Current Report | 3 | SEC Filings | ||
| 23.02. | Bioxytran, Inc.: Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus | 520 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 23, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated... ► Artikel lesen | |
| 17.02. | Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement | 1.547 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 17, 2026 / Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications... ► Artikel lesen | |
| 11.02. | Bioxytran, Inc: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran | 411 | JCN Newswire | BOSTON, Feb 11, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization... ► Artikel lesen | |
| 11.02. | BIOXYTRAN, INC - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | Bioxytran, Inc.: Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference | 351 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 4, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company focused on the development of novel carbohydrate-based therapeutics, today announced... ► Artikel lesen | |
| 02.02. | Bioxytran, Inc.: Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics | 360 | ACCESS Newswire | NEEDHAM, MA / ACCESS Newswire / February 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology... ► Artikel lesen | |
| 29.01. | Bioxytran, Inc.: Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline | 364 | ACCESS Newswire | Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseases NEEDHAM, MA / ACCESS Newswire / January... ► Artikel lesen | |
| 05.01. | BIOXYTRAN, INC - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | BIOXYTRAN, INC - 8-K, Current Report | - | SEC Filings | ||
| 29.10.25 | Bioxytran, Inc.: Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug | 145 | GlobeNewswire (Europe) | Data from the dose optimization trial expected soonProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.... ► Artikel lesen | |
| 15.08.25 | Bioxytran, Inc.: Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation | 468 | GlobeNewswire (Europe) | Game changer for stroke, Alzheimer's, and beyond Shifting from peripheral to tissue-specific oxygenation monitoring BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:... ► Artikel lesen | |
| 03.06.25 | Bioxytran, Inc.: Bioxytran's Groundbreaking Stroke & Alzheimer's Tech Gains Validation That Measures Oxygenation Uptake During Strokes | 185 | GlobeNewswire (Europe) | Mongolian Gerbil Research Unlocks Critical Insights for Ischemic Stroke and Neurodegenerative Disease Treatments BOSTON, MASSACHUSETTS, June 03, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,465 | -0,44 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,560 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| HCW BIOLOGICS | 1,210 | -0,82 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,09 | -0,06 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| PRAXIS PRECISION MEDICINES | 341,89 | -0,20 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 66,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| BIONTECH | 76,40 | -2,98 % | HV-Termine: Hauptversammlungen u.a. bei Aixtron, BioNTech, BMW, Dt. Börse, Deutz, Freenet, K+S, Lufthansa, MuM, Rheinmetall | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,710 | +0,09 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| NUVALENT | 102,40 | +0,10 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| JADE BIOSCIENCES | 23,355 | 0,00 % | Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update | Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,205 | +0,04 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TYRA BIOSCIENCES | 37,070 | +0,08 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| KYMERA THERAPEUTICS | 82,25 | +0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| BEAM THERAPEUTICS | 27,945 | +0,05 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy |
Das Unternehmen BIOXYTRAN INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOXYTRAN INC finden Sie auf Wallstreet Online.